VMD

• Viemed Healthcare, Inc. filed a Form 8-K on August 20, 2026, to furnish its August 2026 investor deck presentation as Exhibit 99.1.
• The company reports a 26% compound annual revenue growth rate since its public listing, $34 million trailing twelve-month free cash flow as of Q2 2026, and no net debt.
• The presentation notes a market cap of approximately $371 million and insider beneficial ownership of over 20%.
• The information is furnished under Item 7.01 (Regulation FD Disclosure) and is not deemed 'filed' for SEC liability purposes.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Net income attributable to Viemed was $2.8 million, or $0.07 per diluted share, for Q2 2026.
• Adjusted EBITDA for Q2 2026 was $13.7 million, down 4.0% from Q2 2025, which included a $1.0 million non-recurring gain.
• The company raised the low end of full-year 2026 net revenue guidance to $314-$320 million and revised Adjusted EBITDA guidance to $64-$68 million.
• Ventilator patients reached a record 12,635 as of June 30, 2026, up 4.0% year-over-year.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• All seven director nominees were elected: Casey Hoyt, W. Todd Zehnder, William Frazier, Randy Dobbs, Nitin Kaushal, Timothy Smokoff, and Sabrina Heltz.
• Sabrina Heltz received the lowest support at 79.76% votes for, with 20.24% withheld.
• Ernst & Young LLP was approved as independent auditors for fiscal year 2026.
• The say-on-pay advisory vote passed with 93.21% votes for.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits

• The company furnished its June 2026 Investor Deck Presentation as Exhibit 99.1, available on its website.
• The presentation highlights Viemed as a national home-based clinical care leader with 26% compounded annual revenue growth since its 2017 public listing.
• As of Q1 2026, Viemed reported $36 million trailing twelve-month free cash flow, no net debt, and over 183,000 patients served across all 50 states.
• The information is furnished, not filed, and the company undertakes no obligation to update it except as required by law.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Net revenue for Q1 2026 was $75.4 million, a 28% increase from $59.1 million in Q1 2025.
• Adjusted EBITDA for Q1 2026 was $14.3 million, up 12% year-over-year.
• Company updated full-year 2026 net revenue guidance to $312-$320 million, narrowed and raised from prior $310-$320 million.
• Adjusted EBITDA guidance for 2026 reaffirmed at $65-$69 million.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Viemed Healthcare, Inc. filed a Form 8-K on March 16, 2026, to disclose its March 2026 Investor Deck Presentation under Item 7.01 Regulation FD Disclosure.
• The presentation highlights Viemed as a national leader in home-based clinical care, serving over 172,000 patients across all 50 states.
• The company reports a 26% compounded annual revenue growth rate since its public listing, $28 million free cash flow in 2025, and no net debt.
• The filing states that the information in Item 7.01 and Exhibit 99.1 is not deemed 'filed' for SEC liability purposes.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Q4 2025 net income attributable to Viemed was $5.6 million ($0.14 per diluted share), up 31%; full-year net income was $14.9 million ($0.37 per diluted share), up 33%.
• Adjusted EBITDA was $18.2 million for Q4 2025 and a record $61.4 million for the full year.
• Full-year 2026 guidance: net revenue of $310-$320 million, Adjusted EBITDA of $65-$69 million, and net capital expenditures of 10%-11.5% of net revenue.
• Board authorized a share repurchase program of up to 1,930,131 common shares on Nasdaq.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits

• The Third Amendment extends the delayed draw term loan commitment expiration date from November 29, 2025 to November 29, 2026.
• The amendment also includes other technical amendments to the Credit Agreement.
• The Credit Agreement is with Regions Bank as administrative agent and collateral agent, and other lenders.
• The Company also released an investor presentation for November 2025, available on its website.

1.01 Entry into a Material Definitive Agreement · 7.01 Regulation FD Disclosure